摘要
目的:观察临床用于心肌梗死患者的治疗,并取得满意疗效的生脉散、越鞠丸、失笑散加减后中药复方对大鼠非梗死区心室肌血管紧张素Ⅱ和醛固酮含量及血管紧张素Ⅱ1型受体mRNA表达的影响,并与阳性药物卡托普利做比较。方法:实验于2000-05/2002-03南方医科大学病理生理教研室完成。①选用健康SD大鼠60只,雌雄各半。按随机摸球法将大鼠分为5组:假手术组,模型组,中药复方高、低剂量组、卡托普利组,每组12只。除假手术组不结扎冠状动脉外,其他组均采用结扎左冠状动脉主干造成心肌梗死模型。术后3d,中药复方高、低剂量组:灌胃10,5g/(kg·d)生脉散、越鞠丸、失笑散加减后中药复方溶液,该复方由广州中医药大学第一附属医院制剂室生产,主要成分为西洋参、黄茂、麦冬、川芍、蒲黄、山楂等;卡托普利组:灌胃10mL/kg卡托普利(上海施贵宝制药公司生产,生产批号:国药准字6M002G,100mg/片)1g/L混悬液;假手术组和模型组:正常饮水。②连续给药8周后,用放射免疫法测定各组大鼠非梗死心肌血管紧张素Ⅱ及醛固酮表达水平,用反转录聚合酶链反应方法检测血管紧张素Ⅱ受体mRNA的表达。③计量资料差异比较采用方差分析。结果:实验过程中假手术组、卡托普利组各死亡4只,模型组、中药复方高剂量组及中药复方低剂量组各死亡5只,最终37只大鼠进入结果分析。①大鼠非梗死区心室肌血管紧张素Ⅱ、醛固酮含量:模型组明显高于其他4组(除外中药复方低剂量组醛固酮含量,P<0.05～0.01)。②大鼠非梗死区心室肌血管紧张素Ⅱ受体mRNA表达:模型组明显高于假手术组(P<0.01),中药复方高剂量组和卡托普利组大鼠明显低于模型组(P<0.05,0.01)。结论:生脉散、越鞠丸、失笑散加减后中药复方可以降低心肌梗死大鼠非梗死区心室肌局部血管紧张素Ⅱ、醛固酮含量,使血管紧张素Ⅱ受体mRNA表达下调,作用结果与卡托普利相同。
AIM： To explore the effects of compound Chinese medicine （Shengmai powder, Yueju pill, Shixiao powder）, which was clinically used in the treatmerit of myocardial infarction （MI）, on angiotensin Ⅱ, .content of aldosterene （ALD） and mRNA expression of angiotensin Ⅱ type 1 receptor in non-infaretion myocardium of rats, and compared with positive drug captopill.
METHODS： The experiment was conducted in the Department of Pathophysiology, Southern Medical University between May 2000 and March 2002.①Sixty healthy SD rats of beth sexes were selected and randomly divided into 5 groups： sham-operation group, model group, high, low dose of compound Chinese medicine group and captopril group with 12 rats in each group. Rats in all groups except the sham-operation group were ligated of the left main coronary artery to establish model of MI. At 3 days after operation, rats in high and low dose compound Chinese medicine groups were given gastric perfusion of 10 g/kg and 5 g/kg of compound Chinese medicine solution, which was manufactured by the Department of Pharmaceutics, First Hospital Affiliated to Guangzhou University of Traditional Chinese Medicine with the main components of xiyangsen, huangmao, maidong, chuanyao, puhuang, shanzha, etc. Rats in the captopill group received gastric perfusion of 10 mL/kg of captopril （manufactured by Shanghai Shiguibao Pharmaceutical Corporation with the batch number of 6M002G, 100 mg/pill） 1 g/L suspension. Rats in sham-operation group and model group were allowed to drinking freely.②After 8 weeks of continuous administration, the levels of angiotensin Ⅱ and expression of aldosterene in non-infaretion myocardium of rats in each group were measured with immunohistochemical method, and RT-PCR was adopted to detect the mRNA expression of angiotensin Ⅱ receptor.③Differences in measurementdata were compared with analysis of variance.
RESULTS： During the experiment, 4 rats in the sham-operation group, 4 rats in the captopril group, 5 rats in model group, 5 rats in high dose compound Chinese medicine group and 5 rats in low dose compound Chinese medicine group died. A total of 37 rats were involved in the analysis of results. ①Levels of angiotensin II and aldosterone in non-infaretion myocardium： those in model group were significantly higher than the other 4 groups （except t he content of aldosterone in low dose compound Chinesemedicine group, P 〈 0.05-0.01）.②Expression of mRNA of angiotensin Ⅱ receptor in non-infarction myocardium： that in the model group was obviously higher than the sham-operation group （P 〈 0.01）, while that in high dose compound Chinese medicine group and captopril group were significantly lower than the model group （P〈 0.05-0.01）.
CONCLUSION： Compound Chinese medicine can reduce the levels ofangiotensin Ⅱ and aldosterone in non-infaretion myocardium of rats with MI, and down-regulate the expression of mRNA of angiotensin Ⅱ receptor,the effect of which is the same as captopril.
出处
《中国临床康复》
CSCD
北大核心
2006年第23期81-83,共3页
Chinese Journal of Clinical Rehabilitation
基金
广东省自然基金资助项目(010627)
广东省中医药局资助项目(010002)~~
